期刊文献+

结核分支杆菌对喹诺酮类药物的耐药分子机制 被引量:1

暂未订购
导出
机构地区 [
出处 《临床肺科杂志》 2003年第6期528-529,共2页 Journal of Clinical Pulmonary Medicine
  • 相关文献

参考文献14

  • 1Hart CA,Beeching NJ,Duerden BI. Tuberculosis into the next century. J med Microbiol, 1996 , 44 : 1 - 34.
  • 2ReichmanLB. Multidrug resistance in the world:the present situation. J chemotherapy, 1996 , 42 ( 12 ) : 2.
  • 3Croflon J,Chanlet P,Maher D,etal. Quinolones for the management of drug-resistant tuberculosis, WHO/TB 196,210 ( 1 ), 1997 : 26.
  • 4Alangaden GJ,Lermer SA. The clinical use of fluoroquinolones for the treatment of Mycobacterial diseases. Clia Infect Dis, 1997,25:1213-1221.
  • 5Maranetra KN. Quinolones and muhidrug-resistant tuberculosis.Chemotherapy, 1999 , 45 (12) : 12 - 18.
  • 6Wang JC. DNA topoisomerases. Annu Rev. Bikchem, 1985,54:665-697.
  • 7Takiff EL, Salazar, Guerrern WM, Huang B, Kreisworth ST et al.Cloning and nucleotide sequece of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Agens Chemother, 1994 , 38: 773 - 780.
  • 8Alangaden G J, Manavathu Ek et al. Characterization of fluoro-quinolone-resistant mutant strains of mycobacterium tuberculosis selected in the laboratory and isolated from patients. Atimicrobial agents and chemotherapy,1995,39(8) :1700-1703.
  • 9Guillemin I,Cambau E,Jarlier V. Sequences of conserved region in the A subunit of DNA Gyrase from Nine Species of the Genus Mycobacterium:Phylogenetic analysis and implication for intr n.sic susceptibility to quinolones. Atimicrobial agents and chemotherapy,1995,39:2145-2149.
  • 10Kgcagoz Y,Hackbarth CJ,et al. Gyrase mutationsin laboratory-selected, fluoroquinoloneresistance mutants of mycobacterium tuberculosis H37Ra. Antimicrobial agents and chemotherapy, 1996 , (8):1768-1774.

同被引文献15

  • 1崔秀琴,肖志坚,郭悦鹏,丁卫民,姚恒波,尚好珍,胡天勇.结核分枝杆菌L型与耐多药肺结核关系的研究[J].医药论坛杂志,2004,25(9):1-3. 被引量:2
  • 2赵云峰,罗永艾.耐药结核病的现状及防治[J].中国实用内科杂志,2004,24(8):451-454. 被引量:8
  • 3FluitAC, VisserMR, SchmitzFJ. Moleculardetecion of ant micro bialresistance[J].Lin Microbio Rew, 2001,14:846 - 871.
  • 4WilliamsDL, SpringL, CollingsL, etal. Contribtion of rpo B mutations to development of rifamycin cross resistance in My cobeuterium tuberculosis [J]. Antincrol, Agents Chemother 1998,42:1853 -1857.
  • 5Watterson SA, Wilson SM, Yates MD, etal comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterinm tuberculosis[J].Clin Microl 1998,1 969 - I 973.
  • 6MikusovaK, SlaydenRA,BesraGS,etal. Biogenesis of the Mycobacterial cell wall and the site ofthambutol[J].Antimicrob Agents Chemother. 1995,39(11):2 484.
  • 7Willia ms KJ, Chan R, Piddock LVJ.grrA of ofloxacic-resistant clinical isolates of Mycobacterium tuberculosis from HongKong[J]. Antimicrob Chemother 1996,37:1 032 - 1 034.
  • 8Morais CJH,Jackson AP. Smith CV, etal. Crystal stucture of the breakage reunion domain of DNA gyrase [J]. Nature 1997,388:903 - 906.
  • 9Caceres NE,Harris NB.Wellehan JF ,etal.overxpression of the D-alanine race mase confers resisters to D-cycloserine in Mycobacterium smegmatis[J].Bacteriol 1997,179:5 046 - 5 055.
  • 10李燕,杨正林,李明远.结核分枝杆菌耐药性的分子机理研究进展[J].微生物学免疫学进展,2000,28(2):85-88. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部